An interventional study of Functional Neurogenesis Stimulation Therapy and placebo control group in Autism Spectrum Disorder, sponsored by Neurocytonix, Inc.. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-12-16.
Sponsored by Neurocytonix, Inc. · Not applicable, Interventional, and Treatment
This study will test whether a noninvasive brain stimulation treatment called Functional Neurogenesis Stimulation (using the NeuroCytontron device) can safely improve core symptoms of Autism Spectrum Disorder (ASD) in children. The study will enroll boys and girls 3 to 12 years old who have ASD (DSM-5 level 1 - 2) and use at least some spoken language. Children may be randomly assigned (like a coin flip) to receive either active NeuroCytotron sessions or sham (placebo) sessions that look the same but deliver no active treatment. Neither the families nor the study staff doing the assessments will know which treatment a child is receiving. The primary question is whether children who receive active treatment exhibit greater improvement in social communication, interaction, and repetitive behaviors compared to children who receive a placebo, as measured by standard autism rating scales.
Each child's participation will last about 3 to 4 months, including screening, 28 days of daily, 1-hour treatment sessions, and follow-up visits up to 12 weeks after the last treatment. During the study, children will undergo physical exams, vital sign assessments, blood and urine tests, brain MRI scans, and electroencephalogram (EEG) recordings to examine brain structure and activity. Some children may need mild sedation or anesthesia for an MRI, which has its own risks. The device utilizes low-energy electromagnetic fields, similar to those used in MRIs. Possible risks include discomfort from lying still, anxiety around the device or MRI scanner, and side effects from sedation or from unexpected changes in behavior or seizures. There may or may not be direct benefit to each child, but information from this study may help researchers develop new, noninvasive treatment options for children with ASD in the future.
1,727 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.
This study's planned enrollment of 256 is above the median of 52 across 1,371 interventional studies indexed under Autism Spectrum Disorder.
Browse Autism Spectrum Disorder studies →Neurocytonix, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
such as severe neurological disorders and difficult-to-control epilepsy.
Group not treated with Functional Neurogenesis Stimulation Therapy (NeuroCytotron)
Other: placebo control group
Group treated with Functional Neurogenesis Stimulation Therapy (NeuroCytotron)
Device: Functional Neurogenesis Stimulation Therapy
NeuroCytotron is a noninvasive investigational medical device that delivers Functional Neurogenesis Stimulation using low-energy, pulsed electromagnetic fields to specific brain regions. For this study, each participant receives one 60-minute treatment session per day for 28 consecutive days. Treatment parameters (field strength, frequency, and beam geometry) are individualized for each child based on their baseline brain MRI to define a three-dimensional target volume. During each session, the child sits or lies comfortably inside the device while the pre-programmed treatment plan is delivered; no surgery, implants, or systemic medications are used.
Also known as: NeuroCytotron
This group will be placed on the device, but will not be treated (placebo group).
Change in Autism Diagnostic Observation Schedule, Second Edition (ADOS-2) total score
ADOS-2 is a standardized, semi-structured assessment that measures social communication, interaction, play, and restricted or repetitive behaviors in individuals with autism spectrum disorder. Higher total scores indicate greater severity of ASD symptoms. The primary outcome is the change in ADOS-2 total score from baseline to 12 weeks post-treatment, comparing participants treated with NeuroCytotron functional neurogenesis stimulation therapy to those treated with placebo. A decrease in score reflects improvement in core ASD symptoms.
Time frame: Baseline (pre-treatment, Days -3 to -1) to 12 weeks after the end of treatment
Change in Childhood Autism Rating Scale, Third Edition (CARS-3) total score
The CARS-3 is a clinician-rated scale with 15 items that assess autism symptom severity based on direct observation. Each item is rated from 1 (within normal limits) to 4 (severely abnormal); total scores range from 15 to 60, with higher scores indicating more severe symptoms of autism. The secondary outcome will be the change in CARS-3 total score from baseline to 12 weeks post-treatment, comparing the NeuroCytotron and placebo groups. A decrease in score reflects improvement in autism severity.
Time frame: Baseline (pre-treatment, Days -3 to -1) to 12 weeks after the end of treatment
Incidence and severity of treatment-emergent adverse events and serious adverse events
Adverse events (AEs) are any untoward medical occurrences in a participant, whether or not related to the investigational device. Serious adverse events (SAEs) include events that result in death, are life-threatening, require or prolong hospitalization, cause significant disability, or are otherwise medically significant. The outcome will summarize the number and percentage of participants with AEs, SAEs, and AEs leading to discontinuation in each group, as well as severity and relationship to study treatment, and overall tolerability based on caregiver/participant reports collected at each visit.
Time frame: From first treatment session (Day 1) through 12-week follow-up (approximately 14 weeks total per participant)
Change in Gilliam Autism Rating Scale, Third Edition (GARS-3) total score
GARS-3 is a standardized rating scale used to identify and assess autism in individuals aged 3 to 22 years. It includes subscales for Social Interaction, Communication, and Stereotyped Behaviors, which contribute to a total score; higher scores indicate a greater likelihood or severity of autism. The secondary outcome is the change in GARS-3 total score from baseline to 12 weeks post-treatment, with lower scores indicating reduced autism-related behaviors, compared between treatment groups.
Time frame: Baseline to 12 weeks after the end of treatment
Change in Adaptive Behavior Assessment System, Third Edition (ABAS-3) composite score
ABAS-3 is a caregiver- or teacher-completed questionnaire that evaluates adaptive functioning across multiple domains (communication, community use, functional academics, home living, health and safety, leisure, self-care, self-direction, social, and work). Higher scores indicate better adaptive functioning. The secondary outcome will be the change in ABAS-3 composite score from baseline to 12 weeks post-treatment, with higher post-treatment scores reflecting improvement, compared between treatment groups.
Time frame: Baseline to 12 weeks after the end of treatment
Change in brain regional volumes on structural MRI
High-resolution structural MRI will be used to quantify the volumes of gray and white matter in cortical, subcortical, and cerebellar regions (e.g., total cortical gray matter, cerebral white matter, thalamus, basal ganglia, hippocampus, amygdala, brainstem, and cerebellum). The exploratory outcome will compare within-subject and between-group changes in regional brain volumes from baseline to 12 weeks post-treatment for NeuroCytotron versus placebo. Increases in gray matter or cerebellar volumes and/or reductions in ventricular volume will be explored as potential markers of structural plasticity associated with treatment.
Time frame: Baseline (pre-treatment) to 12 weeks after the end of treatment
Change in white matter integrity on diffusion tensor imaging (DTI)
Diffusion tensor imaging will be used to assess white matter integrity using metrics such as fractional anisotropy (FA) and mean diffusivity (MD) in major white matter tracts related to cognitive and sensorimotor functions. Tract-based and connectome analyses will examine changes in FA, MD, and streamline counts between baseline and 12 weeks post-treatment. This exploratory outcome will compare changes in these DTI metrics between NeuroCytotron and placebo groups as potential indicators of treatment-related changes in structural connectivity.
Time frame: Baseline to 12 weeks after the end of treatment
Change in EEG spectral power, connectivity, and event-related potentials
Resting-state EEG will be recorded using a 19-channel 10-20 system at baseline, after the last treatment session (Day 28), and during follow-up visits. Exploratory analyses will include (1) spectral power in standard frequency bands (delta, theta, alpha, beta); (2) functional connectivity metrics such as coherence and phase synchronization between key regions (e.g., frontal-parietal, fronto-temporal); and (3) event-related potentials (e.g., P300, N200) where applicable. The outcome will describe within-subject trajectories and between-group differences in these EEG measures over time as potential biomarkers of neurophysiological response to NeuroCytotron versus placebo.
Time frame: Baseline, end of treatment (Day 28), and 4, 8, and 12 weeks after the end of treatment
Change in comorbid symptoms (anxiety, depression, sleep) and sensory processing difficulties
Exploratory outcomes will include changes in comorbid symptoms commonly associated with ASD-such as anxiety, depressive symptoms, and sleep disturbances-plus changes in sensory processing difficulties (hypersensitivity or hyposensitivity). These domains will be assessed with caregiver-reported standardized questionnaires, including sensory processing tools such as the Sensory Profile. Changes in questionnaire scores from baseline to 12 weeks post-treatment will be summarized and compared between the NeuroCytotron and placebo groups to explore broader functional effects of treatment beyond core ASD symptoms.
Time frame: Baseline to 12 weeks after the end of treatment
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neurocytonix, Inc.